Nykredit A S Takes $205.77 Million Position in Pfizer Inc. $PFE

Nykredit A S acquired a new position in Pfizer Inc. (NYSE:PFE) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,545,428 shares of the biopharmaceutical company’s stock, valued at approximately $205,774,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Godfrey Financial Associates Inc. bought a new position in Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC purchased a new stake in Pfizer during the 2nd quarter valued at approximately $26,000. Field & Main Bank bought a new stake in shares of Pfizer during the second quarter valued at approximately $27,000. HFM Investment Advisors LLC lifted its holdings in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. lifted its holdings in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on PFE shares. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and cut their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Wolfe Research reissued an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. JPMorgan Chase & Co. cut their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, BMO Capital Markets decreased their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.28.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly performance: Pfizer reported earnings and revenue above expectations, with quarterly revenue increasing year over year. The results, along with growth in vaccines and oncology, have helped drive renewed investor interest. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Legal overhang reduced: Pfizer’s reported settlement of more than 6,000 Depo-Provera lawsuits removes some litigation uncertainty and may be viewed favorably by investors. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Pipeline activity: Pfizer has begun a Phase 1 study of asthma candidate PF-08103402. Although early-stage programs are not near-term revenue drivers, the trial provides another potential growth asset as the company works to offset future patent expirations. Pfizer’s New Asthma Candidate PF-08103402 Enters Phase 1
• Neutral Sentiment: Valuation and dividend appeal: A bullish investment case argues that PFE remains attractive below $30 for patient, income-oriented investors, supported by its dividend and long-term recovery potential. Should You Buy Pfizer Stock Below $30?
• Negative Sentiment: Growth concerns persist: Commentary highlights declining core-business revenue and the approaching patent cliff. Pfizer’s AI strategy is viewed as a longer-term promise rather than evidence of immediate earnings growth. Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
• Negative Sentiment: Bearish sentiment remains visible: Jim Cramer declined to recommend Pfizer despite its dividend, while unusually high put-option activity suggests some traders are positioning for downside or hedging near the recent high. Cramer Won’t Recommend Pfizer Even With Its Dividend

Pfizer Price Performance

Pfizer stock opened at $29.02 on Thursday. The company has a market cap of $165.42 billion, a price-to-earnings ratio of 38.19, a PEG ratio of 1.92 and a beta of 0.34. The firm’s fifty day moving average is $25.79 and its 200 day moving average is $26.32. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $29.09.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the company posted $0.78 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were given a $0.43 dividend. The ex-dividend date was Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 5.9%. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.